Literature DB >> 29603365

Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?

Wah-Kheong Chan1, Nik Raihan Nik Mustapha1, Sanjiv Mahadeva1, Vincent Wai-Sun Wong2,3, Jenny Yeuk-Ki Cheng2,3, Grace Lai-Hung Wong2,3.   

Abstract

BACKGROUND AND AIM: There are limited studies on controlled attenuation parameter (CAP) using Fibroscan XL probe for the diagnosis of hepatic steatosis grade. The aim of this study was to determine whether previously defined optimal cut-offs for CAP using the M probe could be applied for the XL probe.
METHODS: Adult patients with chronic liver disease who had a liver biopsy and examination with both the M and XL probes were included. Previously defined optimal cut-offs for CAP using the M probe were used for the diagnosis of steatosis grades ≥S1, ≥S2, and S3 (248, 268, and 280 dB/m, respectively).
RESULTS: Data for 180 patients were analyzed (mean age 53.7 ± 10.8 years; central obesity 84.5%; non-alcoholic fatty liver disease 86.7%). The distribution of steatosis grades was S0, 9.4%; S1, 28.3%; S2, 43.9%, and S3, 18.3%. The sensitivity, specificity, positive predictive value, and negative predictive value of CAP using the M/XL probe for the diagnosis of steatosis grade ≥S1 was 93.9%/93.3%, 58.8%/58.8%, 95.6%/95.6%, and 50.0%/47.6%, respectively. These values were 94.6%/94.6%, 41.2%/44.1%, 72.6%/73.6%, and 82.4%/83.3%, respectively, for ≥S2, and 87.9%/87.9%, 27.2%/27.9%, 21.3%/21.5%, and 90.9%/91.1%, respectively, for S3.
CONCLUSION: The same cut-off values for CAP may be used for the M and XL probes for the diagnosis of hepatic steatosis grade.
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  CAP; M probe; XL probe; controlled attenuation parameter; fibroscan; steatosis

Mesh:

Year:  2018        PMID: 29603365     DOI: 10.1111/jgh.14150

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

1.  Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.

Authors:  Jing-Houng Wang; Hsin-You Ou; Yi-Hao Yen; Chien-Hung Chen; Sheng-Nan Lu
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

Review 2.  The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature.

Authors:  Max M Puthenpura; Vishal Patel; John Fam; Leon Katz; David S Tichansky; Stephan Myers
Journal:  Obes Surg       Date:  2020-09-26       Impact factor: 4.129

3.  Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study.

Authors:  Satoshi Oeda; Hirokazu Takahashi; Kento Imajo; Yuya Seko; Yuji Ogawa; Michihisa Moriguchi; Masato Yoneda; Keizo Anzai; Shinichi Aishima; Masayoshi Kage; Yoshito Itoh; Atsushi Nakajima; Yuichiro Eguchi
Journal:  J Gastroenterol       Date:  2019-10-25       Impact factor: 7.527

4.  New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode.

Authors:  Yohei Koizumi; Masashi Hirooka; Nobuharu Tamaki; Norihisa Yada; Osamu Nakashima; Namiki Izumi; Masatoshi Kudo; Yoichi Hiasa
Journal:  PLoS One       Date:  2019-08-27       Impact factor: 3.240

Review 5.  Application of transient elastography in nonalcoholic fatty liver disease.

Authors:  Xinrong Zhang; Grace Lai-Hung Wong; Vincent Wai-Sun Wong
Journal:  Clin Mol Hepatol       Date:  2019-11-08

Review 6.  Non-alcoholic fatty liver disease in lean individuals.

Authors:  Somaya Albhaisi; Abhijit Chowdhury; Arun J Sanyal
Journal:  JHEP Rep       Date:  2019-08-30

7.  Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.

Authors:  Rasha R El-Kady; Amani K Ali; Lamia M El Wakeel; Nagwa A Sabri; May A Shawki
Journal:  Ther Adv Chronic Dis       Date:  2022-02-23       Impact factor: 5.091

8.  Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).

Authors: 
Journal:  Eat Weight Disord       Date:  2021-12-16       Impact factor: 3.008

9.  Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience.

Authors:  Ioan Sporea; Ruxandra Mare; Alina Popescu; Silviu Nistorescu; Victor Baldea; Roxana Sirli; Adina Braha; Alexandra Sima; Romulus Timar; Raluca Lupusoru
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

Review 10.  Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease.

Authors:  Amir M Pirmoazen; Aman Khurana; Ahmed El Kaffas; Aya Kamaya
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.